Tremelimumab

曲麦利尤单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameTremelimumab
Drug Alias Name替西木单抗CP-675206 clone 11.2.1TicilimumabCP-675,206Anti CTLA 4 monoclonal antibody-Pfizer +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsBone metastasesEsophageal adenocarcinomaMetastatic breast cancer +[81] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Hepatocellular
Approved Indications in ChinaCarcinoma, Hepatocellular
Original Approved Country/TerritoryUnited States
Original Approved Date2022/10/21
Country/TerritoryCzechiaBelgiumBulgaria +[53] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedimmune Llc Boehringer Ingelheim Pharma Gmbh & Co KgUtah State UniversityUniversity of Sydney +[30] 
Inactive CompaniesWashington University School Of MedicineYale UniversityPfizer Inc +[15] 
Active IndicationsEsophageal adenocarcinomaMetastatic breast cancerOropharyngeal Squamous Cell Carcinoma (OPSCC) +[63] 
Inactive IndicationsBone metastasesSkin MelanomaGastroesophageal Junction Neoplasms +[18] 

Other Information

ATC CodeL01FX20
Related LinksWikipediaDrugBankKEGG